Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$1.78 +14.1%	$1.23	$0.81 ▼ $1.84	$36.90M	0.8	400,446 shs	922,024 shs
FGEN FibroGen	$9.48 -4.0%	$6.91	$4.50 ▼ $21.94	$39.95M	0.76	52,847 shs	52,323 shs
INTI Inhibitor Therapeutics	$0.04 -20.2%	$0.05	$0.03 ▼ $0.10	$8.46M	-0.42	4,376 shs	12,000 shs
MAAQ Mana Capital Acquisition	$3.74 +7.5%	$4.03	$5.35 ▼ $10.25	$30.39M	N/A	33,075 shs	56,344 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	+14.10%	+31.85%	+44.72%	+78.00%	+42.40%
FGEN FibroGen	-4.05%	+19.40%	+29.51%	+23.92%	+4.58%
INTI Inhibitor Therapeutics	-20.20%	-16.81%	-20.20%	-30.18%	-36.70%
MAAQ Mana Capital Acquisition	0.00%	-5.08%	-9.88%	-6.50%	+790.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENLV Enlivex Therapeutics	3.3385 of 5 stars	3.7	5.0	0.0	0.0	3.0	0.8	0.6
FGEN FibroGen	4.6157 of 5 stars	3.3	5.0	0.0	4.7	2.2	3.3	0.6
INTI Inhibitor Therapeutics	0.0855 of 5 stars	0.0	3.0	0.0	0.0	0.6	0.0	0.0
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	461.80% Upside
FGEN FibroGen	2.50	Moderate Buy	$43.00	353.59% Upside
INTI Inhibitor Therapeutics	0.00	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INTI, FGEN, MAAQ, and ENLV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$43.00
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
FGEN FibroGen	$29.62M	1.29	N/A	N/A	($50.08) per share	-0.19
INTI Inhibitor Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
FGEN FibroGen	-$47.58M	-$0.38	N/A	N/A	N/A	-3.86%	N/A	-27.34%	N/A
INTI Inhibitor Therapeutics	-$3.34M	-$0.01	N/A	∞	N/A	N/A	-153.29%	-62.09%	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest INTI, FGEN, MAAQ, and ENLV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	FGEN FibroGen	-$2.25	-$3.38	-$1.13	-$1.88	$2.88 million	$1.30 million
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
INTI Inhibitor Therapeutics	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	7.20	7.20
FGEN FibroGen	N/A	1.04	1.98
INTI Inhibitor Therapeutics	N/A	46.68	46.68
MAAQ Mana Capital Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
FGEN FibroGen	72.71%
INTI Inhibitor Therapeutics	N/A
MAAQ Mana Capital Acquisition	68.44%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
FGEN FibroGen	3.07%
INTI Inhibitor Therapeutics	4.60%
MAAQ Mana Capital Acquisition	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
INTI Inhibitor Therapeutics	1	172.57 million	164.64 million	Not Optionable
MAAQ Mana Capital Acquisition	1	8.13 million	N/A	Not Optionable

INTI, FGEN, MAAQ, and ENLV Headlines

Recent News About These Companies

MANA Projects Continues Growth Trajectory with 2.5-Acre Land Acquisition Near Sarjapur Road

September 22, 2024 | news.webindia123.comN

Decentraland (CRYPTO: MANA)

April 10, 2024 | fool.com

Bernhard Capital sees acquisition potential for energy efficiency software business

September 26, 2023 | pehub.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INTI, FGEN, MAAQ, and ENLV Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$1.78 +0.22 (+14.10%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.77 -0.01 (-0.34%)

As of 08/14/2025 07:58 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

FibroGen NASDAQ:FGEN

$9.48 -0.40 (-4.05%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$9.36 -0.12 (-1.22%)

As of 08/14/2025 07:03 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Inhibitor Therapeutics OTCMKTS:INTI

$0.04 -0.01 (-20.20%)

As of 08/14/2025 03:35 PM Eastern

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

Mana Capital Acquisition NASDAQ:MAAQ

$3.74 +0.26 (+7.47%)

As of 08/12/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time